Drogas emergentesuna perspectiva medicolegal

  1. García-Repetto, Rosario
  2. Soria Sánchez, M. Luisa
Revista:
Revista española de medicina legal: órgano de la Asociación Nacional de Médicos Forenses

ISSN: 0377-4732

Año de publicación: 2011

Volumen: 37

Número: 2

Páginas: 76-82

Tipo: Artículo

DOI: 10.1016/S0377-4732(11)70067-0 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista española de medicina legal: órgano de la Asociación Nacional de Médicos Forenses

Resumen

La continua aparición de nuevas sustancias sintéticas que puedan ser utilizadas como drogas de abuso supone un desafío constante para el toxicológo forense. Un reciente informe del Observatorio Europeo para Drogas y Toxicomanías pone de manifesto esta situación, ya que durante el año 2008 aparecieron en el mercado 13 sustancias psicoactivas nuevas, 11 de ellas sintéticas y 2 productos vegetales. Estas sustancias son conocidas como drogas emergentes. Todas ellas tienen en común que existe un amplio desconocimiento de sus propiedades toxicológicas, no están reguladas en la mayoría de los países y se pueden obtener fácilmente a través de internet. En el presente trabajo se revisan los conocimientos existentes hasta el momento sobre estas sustancias, haciendo hincapié en los aspectos medicolegales de estas.

Referencias bibliográficas

  • Haroz R, Greenberg ML. Emerging drugs of abuse. Med Clin North Am. 2005;89:1259-76.
  • Peters FT, Martínez-Ramírez J. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit. 2010;32:532-8.
  • Gussow L. Coming soon to an ED near you: Bromo-Dragonfly (not an insect), K2 (not a mountain) and Venus (not the planet). Emer Med News. 2010;32:20-1.
  • European Monitoring Centre for Drugs and Drugs of Abuse, Annual Report 2009: The state of the drug problem in Europe, Office for Official Publications of the European Communities, Luxembourg, 2009 [citado 1 Mar 2011]. Disponible en: http:// www.emcdda.europa.eu/publications/annual-report/2009
  • Schmidt MM, Sharma A, Schifano F, Feinmann C. “Legal highs” on the net. Evaluation of UK based websites, products and product information. Forensic Sci Int. 2011 [en prensa].
  • Maurer HH, Kraemer T, Sprienger D, Staack R. Chemistry, phar- macology, toxicology and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazines and pyrrolidinophenone types. A synopsis. Ther Drug Monit. 2004;26:127-30.
  • Bye C, Munro FA, Peck AW. A comparison of the effects of 1-bencylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol. 1973;6:163-9.
  • Campbell H, Cline W, Evans M. Comparison of the effects of dexamphetamine and 1-bencylpiperazine in former addicts. Eur J Clin Pharmacol. 1973;6:170-6.
  • Hashimoto K, Maeda H, Goromaru T. Effects of benzylpiperazine derivatives on neurotoxicity of 3, 4-methylenedioxymetam- phetamine in rat brain. Brain Res. 1992;590:341-4.
  • Murphy DL, Lesch KP, Aulakh CS. Serotonin-selective arylpiperazine with neuroendocrine, behavioural, temperature and cardiovascular effects in human. Pharmacol Rev. 1991;43: 527-52.
  • Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001;65:97-101.
  • Acuña-Castillo C, Villalobos C, Moya PR. Differences in potency and efficacy of a series of phenylisopropylamine/phenetylamine pairs and 5-HT (2A) and 5-HT (2C) receptors. Br J Pharma- col. 2002;136:510-9.
  • Maddox VH, Godefroi EF, Parcell RF. Synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem. 1965;8:230-5.
  • Maurer HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monitor. 2010;32:544-9.
  • Monte AP, Marona-Lewicka D, Parker MA. Dihydrobenzofuran analogues of hallucinogens 3. Models of 4-substituted (2,5-dimethoxypehynl)alkylamine derivatives with rigified methoxy gropus. J Med Chem. 1996;39:2953-61.
  • Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ. 2010;340:1605.
  • Vardakou I, Pistos C, Spiliopoilou Ch. Drugs for youth via Internet and the example of mephedrone. Toxicol Let. 2011;201: 191-5.
  • Parker A, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor J Med Chem. 1998;41:5148-9.
  • Mustata C, Torrens M, Pardo R, Pérez C, Farré M. Spice drugs: los cannabinoides como nuevas drogas de diseño. Adicciones. 2009;21:181-6.
  • Stafford GI, Pedersen ME, Van Staden J, Jäger A. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J Ethnopharmacology. 2008;119:513-7.
  • European Monitoring Centre for Drugs and Drugs of Abuse. Actions on new drugs briefing paper: Understanding the Spice Phenomenon. Updated version: 9 Jun 2009.
  • Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreiros N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spec. 2009;44:832-7.
  • Babu K, Boyer E, Hernon C, Brush E. Emerging drugs of abuse. Clin Ped Emerg Med. 2005;6:81-4.
  • Yan F, Roth BL, Salvinorin A. A novel and highly selective kappaopioid receptor agonist. Life Sci. 2004;75:2615-9.
  • Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ehtnopharmacol. 1994;43:53-6.
  • Matsumoto K, Horie S, Ishikawa H. Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally activ opioid analgesic from de Thai medicinal herb Mitragyna speciosa. Life Sci. 2004;74:2143-55.
  • Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant Mitagyna speciosa. Chem Pharm Bull. 2004;52:916-28.
  • European Monitoring Centre for Drugs and Drugs of Abuse. Re- port on the risk assessment of BZP in the framework of the Council Decision on new psychoactive substances. Office for Official Publications of the European Communities. Luxembourg; 2009.
  • The Misuse of Drugs Act 1971 (Amendement) Order 2009, 2009.
  • Orden SAS/1916/2009 de 8 de julio (BOE 17 de julio de 2009). Disponible en: http://www.boe.es/boe/dias/2009/07/17/ pdfs/BOE-A-2009-11877.pdf
  • Orden SPI/201/2011 de 3 de febrero (BOE 9 de febrero de 2011). Disponible en: http://www.boe.es/boe/dias/ 2011/02/09/pdfs/BOE-A-2011-2490.pdf
  • De Paoli G, Maskell PD, Pounder D. Naphyrone: Analytical Profile of the new “legal high” substitute for mephedrone. J Fo- rensic Legal Med. 2011;18:93.
  • Garcia-Repetto R, Moreno E, Soriano T, Jurado C, Giménez MP, Menendez M. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int. 2003;135:110-4.
  • Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol. 2001;25:649-51.
  • Lir RH, Liu HC, Lin DL. Distribution of MDMA and MDA in postmortem and antemortem specimens. J Anal Toxicol. 2006;30:545-50.
  • Rogers G, Elston J, Garside R, Roone C, Taylor R, Younger R, et al. The harmful effects of recreational ecstasy: a systematic review of observational evidence. Heatlg Technol Asses. 2009;13:1-315.
  • Wikström M, Holmgren P, Ahlner J. A2 (N-Benzylpiperazine) a New Drug of Abuse in Sweden. J Anal Toxicol. 2004;28:67-70. 38. Wood D, Dargan P, Button J, Holt D, Ovaska H, Ramsey J, et al. Collapse, reported seizure and an unexpected pill. Lancet. 2007;369:1490.
  • Elliot S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol. 2008;32:172-7.
  • Kovaleva J, Devyst E, De Paepe P, Vestraete A. Acute Cloro- phenylpiperazine overdose: A case report and review of the literature. Ther Drug Monitor. 2008;30:394-8.
  • Europol-EMCDDA Joint Report on a new psychoactive drug: 4-methylcathinone (mephedrone) [citado 30 Oct 2010]. Disponible en: http://www.emcdda.europa.eu/html.cfm/in- dex116639EN.html
  • Wood DM, Greene SL, Dargon PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2010. Disponible en: http://emj.bmj.com/con- tent/early/2010/06/25/emj.2010.092288.html
  • Torrance H, Cooper G. Detection of mephedrone (4-methylcathinone) in 4 fatalities in Scotland. Forensic Sci Int. 2010;202: 62-3.
  • Gibbons S, Zloh M. An analysis of the legal high mephedrone. Bioorganic & Medicinal Chemistry Letters. 2010;20:4135-9.
  • Dickson AJ, Vorce SP, Levine B, Past M. Multiple drug toxicity caused by the coadministration of 4-methylcathinone (Mephedrone) and Heroin. J Anal Toxicol. 2010;34:162-8.
  • Lusthof KJ, Oosting R, Maes A, Verschaagen M, Dijkhuizen A, Sprong A. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int. 2011 [en prensa].
  • Wood DM, Looker J, Skaikh, Bulton J, Puchnarewicz M, Davies S, et al. Delayed onset of seizures and toxicology associated with recreational use of Bromo Dragon FLY. J Med Toxicol. 2009;5:226-9.
  • Andreasen MF, Telving R, Bikler RI, Schumarter B, Johannsen M. A fatal poisoning involving Bromo-DragonFly. Forensic Sci Int. 2009;183:91-6.
  • Vearrier D, Osterhoudt K. A teenager with agitation. Ped Emer Care. 2010;26:462-
Fuente de los datos: Dialnet